ArticleDiscover oncology2025
Bibliometric analysis of global research on breast cancer with HER2-low expression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe abnormal expression of Human Epidermal Growth Factor Receptor 2 (HER2) is closely related to the prognosis of breast cancer. Since the concept of HER2-low expression was introduced in 2018, researches on HER2-low expression breast cancer have burgeoned. This bibliometric analysis seeks to evaluate the worldwide distribution of literature, research focuses, and upcoming trends in HER2-low expression breast cancer research.
methodsWe extensively searched for articles on HER2-low expression breast cancer from January 2018 to March 2025 using the Web of Science database. By employing the Bibliometrix, VOSviewer and CiteSpace, we systematically examined information regarding countries, institutions, authors, journals, and keywords.
resultsA total of 573 literature on HER2-low expression breast cancer was included. These literature come from 54 countries, 1145 institutions, and 4125 authors. China and the United States emerge as leading contributors to this field, with the Harvard University being the most prolific institution.Curigliano is the most influential scholar in this research domain.The leading journals in terms of literature sources are CANCERS and FRONTIERS IN ONCOLOGY.The most cited reference is "Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer".Keyword analysis indicates that the research emphasis has shifted towards "prognostic factor", "immunohistochemistry", "targeted therapy", "diagnosis", "guideline", "overall survival" and "pathological complete response" in recent years.
conclusionThis study applies bibliometric tools to analyze the literature on HER2-low expression breast cancer, which shows a notable upward trend and highlights the clinical significance, providing researchers with the priorities and hotspots in this crucial field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.